-continued

<400> SEQUENCE: 56

His His His His His His
1 5

<210> SEQ ID NO 57
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 57

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15

We claim:

1. A method for treating headache in an individual, comprising:

administering to the individual an effective amount of a humanized monoclonal anti-Calcitonin Gene-Related Peptide (CGRP) antagonist antibody, comprising:

two human IgG heavy chains, each heavy chain comprising three complementarity determining regions (CDRs) and four framework regions, wherein portions of the two heavy chains together form an Fc region; and

two light chains, each light chain comprising three CDRs and four framework regions;

wherein the CDRs impart to the antibody specific binding to a CGRP consisting of amino acid residues 1 to 37 of SEQ ID NO:15 or SEQ ID NO:43.

2. The method of claim **1**, wherein the antibody is formulated with a pharmaceutically acceptable carrier, excipient, or stabilizer.

3. The method of claim **1**, wherein the antibody is administered systemically, intravenously, subcutaneously, intramuscularly, or transdermally.

4. The method of claim **1**, wherein the antibody is administered intravenously or subcutaneously.

5. The method of claim **1**, wherein the headache is a migraine with or without aura, hemiplegic migraine, cluster headache, migrainous neuralgia, chronic headache, or tension headache.

6. The method of claim **1**, wherein the headache is a migraine.

7. The method of claim **1**, wherein the antibody is administered at a dose of at least 3 μg/kg.

8. The method of claim **1**, wherein constant regions of the IgG heavy chains are IgG1 constant regions.

9. The method of claim **8**, wherein the CDRs impart to the antibody specific binding to a fragment of the CGRP comprising amino acid residues 8 to 37 of SEQ ID NO:15.

10. The method of claim **8**, wherein the CDRs of the humanized monoclonal antibody are derived from mouse, rat, or rabbit CDRs.

11. The method of claim **1**, wherein constant regions of the IgG heavy chains are IgG2 constant regions.

12. The method of claim **11**, wherein the CDRs impart to the antibody specific binding to a fragment of the CGRP comprising amino acid residues 8 to 37 of SEQ ID NO:15.

13. The method of claim **11**, wherein the CDRs impart to the antibody specific binding to a fragment of the CGRP comprising amino acid residues 33 to 37 of SEQ ID NO:15.

14. The method of claim **11**, wherein the CDRs of the humanized monoclonal antibody are derived from mouse, rat, or rabbit CDRs.

15. The method of claim **1**, wherein constant regions of the IgG heavy chains are IgG4 constant regions.

16. The method of claim **15**, wherein the CDRs impart to the antibody specific binding to a fragment of the CGRP comprising amino acid residues 8 to 37 of SEQ ID NO:15.

17. The method of claim **15**, wherein the CDRs of the humanized monoclonal antibody are derived from mouse, rat, or rabbit CDRs.

18. The method of claim **15**, wherein a constant region of the antibody comprises a mutation in an oligosaccharide attachment amino acid residue that is part of an N-glycosylation recognition sequence in the constant region.

* * * * *